[HTML][HTML] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz, H Debbabi, BI Levy - Annals of Oncology, 2008 - elibrary.ru
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
[引用][C] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ MOURAD, G DES GUETZ, H DEBBABI… - Annals of …, 2008 - pascal-francis.inist.fr
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for
microcirculation CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
microcirculation CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
[PDF][PDF] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz, H Debbabi, BI Levy - Annals of Oncology, 2008 - academia.edu
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz… - Annals of oncology …, 2008 - pubmed.ncbi.nlm.nih.gov
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
[引用][C] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz, H Debbabi, BI Levy - Annals of Oncology, 2008 - cir.nii.ac.jp
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for
microcirculation | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
microcirculation | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.
JJ Mourad, G des Guetz, H Debbabi… - Annals of Oncology …, 2007 - europepmc.org
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
[PDF][PDF] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz, H Debbabi, BI Levy - Annals of Oncology, 2008 - researchgate.net
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz, H Debbabi… - Annals of …, 2008 - annalsofoncology.org
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
[PDF][PDF] Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
JJ Mourad, G des Guetz, H Debbabi, BI Levy - Annals of Oncology, 2008 - researchgate.net
Arterial hypertension (HT) has been reported in all studies involving bevacizumab, an
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …
antiangiogenic agent designed to target vascular endothelial growth factor (VEGF). The …